Anthony Zietman, MD, of Massachusetts General Hospital, discusses the practice-changing results from a study comparing fractionation schedules in patients with low-risk prostate cancer (Abstract LBA6).
Supriya Chopra, MD, of Tata Memorial Hospital, discusses results of the PARCER study, which compared conventional 3D conformal radiotherapy to image-guided intensity-modulated radiotherapy in reducing bowel side effects for women with cervical cancer (Abstract 8).
Bruce Minsky, MD, of MD Anderson Cancer Center, discusses two important papers: results from a prospective trial on quality-of-life outcomes for low-risk HPV-associated oropharyngeal squamous cell carcinoma, and a prostate cancer radiation therapy study (Abstracts 3, 4).
Reshma Jagsi, MD, DPhil, of the University of Michigan Health System, discusses this multicenter phase 1 study of veliparib given concurrently with chest wall and nodal radiation therapy in patients with inflammatory or locoregionally recurrent breast cancer (Abstract 312).
Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, oropharyngeal squamous cell carcinoma, and breast cancer (Abstracts 215, 3, and LBA7).
Brian D. Kavanagh, MD, of the University of Colorado School of Medicine, summarizes three papers: outcomes for locally advanced non–small cell lung cancer, 3D CRT vs image-guided intensity-modulated radiotherapy for reducing bowel toxicity, and dexamethasone for controlling pain flares in patients with bone metastases (Abstracts 2, 8, LBA6663).
